



## Nurix Therapeutics to Participate in Upcoming Investor Conference

April 7, 2026

BRISBANE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 25<sup>th</sup> Annual Needham Virtual Healthcare Conference in April.

- **Needham Virtual Healthcare Conference**

Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix  
Monday, April 13, 2026, at 1:30 – 2:10 p.m. ET

The fireside chat will be webcast live and may be viewed via a link in the [Investors](#) section of the Nurix website. The archived webcast will be available for 30 days after the event.

### **About Nurix Therapeutics, Inc.**

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix's partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6 in collaboration with Sanofi, a clinical stage degrader of IRAK4 in collaboration with Gilead, as well as additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine's next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit <http://www.nurixtx.com>.

### **Contacts:**

#### **Investors**

Kris Fortner  
Nurix Therapeutics, Inc.  
[kfortner@nurixtx.com](mailto:kfortner@nurixtx.com)

Sylvia Wheeler  
Wheelhouse Life Science Advisors  
[swheeler@wheelhousesa.com](mailto:swheeler@wheelhousesa.com)

#### **Media**

Aljanae Reynolds  
Wheelhouse Life Science Advisors  
[areynolds@wheelhousesa.com](mailto:areynolds@wheelhousesa.com)

Kris Fortner  
Nurix Therapeutics, Inc.  
[kfortner@nurixtx.com](mailto:kfortner@nurixtx.com)